Letarte N - Search Results

1

An evaluation of pharmacists' expectations towards pharmacogenomics.

de Denus S, Letarte N, Hurlimann T, Lambert JP, Lavoie A, Robb L, Sheehan NL, Turgeon J, Vadnais B. de Denus S, et al. Among authors: letarte n. Pharmacogenomics. 2013 Jan;14(2):165-75. doi: 10.2217/pgs.12.197. Pharmacogenomics. 2013. PMID: 23327577

2

Opinion, experience and educational preferences concerning pharmacogenomics: an exploratory study of Quebec pharmacists.

Meloche M, Kwon HJ, Letarte N, Bussières JF, Vadnais B, Hurlimann T, Lavoie A, Beauchesne MF, de Denus S. Meloche M, et al. Among authors: letarte n. Pharmacogenomics. 2020 Mar;21(4):235-245. doi: 10.2217/pgs-2019-0135. Epub 2020 Feb 20. Pharmacogenomics. 2020. PMID: 32077363

3

[Data regarding the roles and impact of pharmaceutical activities: Quantitative and qualitative study with four groups of experts].

Breton M, Ferreira E, Letarte N, Bussières JF. Breton M, et al. Among authors: letarte n. Ann Pharm Fr. 2017 Mar;75(2):152-162. doi: 10.1016/j.pharma.2016.09.003. Epub 2016 Nov 14. Ann Pharm Fr. 2017. PMID: 27855948 French.

4

A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.

Beauchemin C, Letarte N, Mathurin K, Yelle L, Lachaine J. Beauchemin C, et al. Among authors: letarte n. J Med Econ. 2016 Jun;19(6):619-29. doi: 10.3111/13696998.2016.1151431. Epub 2016 Mar 2. J Med Econ. 2016. PMID: 26850287 Free article.

5

Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available.

Beauchemin C, Lapierre MÈ, Letarte N, Yelle L, Lachaine J. Beauchemin C, et al. Among authors: letarte n. Pharmacoeconomics. 2016 Sep;34(9):889-900. doi: 10.1007/s40273-016-0401-4. Pharmacoeconomics. 2016. PMID: 27002517 Review.

6

Safe administration of docetaxel after weekly paclitaxel-induced acute pancreatitis.

Adam JP, Gauthier P, Letarte N. Adam JP, et al. Among authors: letarte n. J Oncol Pharm Pract. 2017 Oct;23(7):540-544. doi: 10.1177/1078155216660184. Epub 2016 Jul 27. J Oncol Pharm Pract. 2017. PMID: 27466225

7

Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.

Adam JP, Boumedien F, Letarte N, Provencher D. Adam JP, et al. Among authors: letarte n. Gynecol Oncol. 2017 Oct;147(1):47-53. doi: 10.1016/j.ygyno.2017.07.123. Epub 2017 Jul 24. Gynecol Oncol. 2017. PMID: 28751117

8

Analyzing temozolomide medication errors: potentially fatal.

Letarte N, Gabay MP, Bressler LR, Long KE, Stachnik JM, Villano JL. Letarte N, et al. J Neurooncol. 2014 Oct;120(1):111-5. doi: 10.1007/s11060-014-1523-1. Epub 2014 Jul 16. J Neurooncol. 2014. PMID: 25026995 Free PMC article.

9

Bevacizumab and central nervous system (CNS) hemorrhage.

Letarte N, Bressler LR, Villano JL. Letarte N, et al. Cancer Chemother Pharmacol. 2013 Jun;71(6):1561-5. doi: 10.1007/s00280-013-2155-4. Epub 2013 Apr 6. Cancer Chemother Pharmacol. 2013. PMID: 23564377 Review.

10

Procarbazine, lomustine and vincristine toxicity in low-grade gliomas.

Jutras G, Bélanger K, Letarte N, Adam JP, Roberge D, Lemieux B, Lemieux-Blanchard É, Masucci L, Ménard C, Bahary JP, Moumdjian R, Berthelet F, Florescu M. Jutras G, et al. Among authors: letarte n. Curr Oncol. 2018 Feb;25(1):e33-e39. doi: 10.3747/co.25.3680. Epub 2018 Feb 28. Curr Oncol. 2018. PMID: 29507493 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page